107 related articles for article (PubMed ID: 26453533)
1. Drug target molecules to guide immunosuppression.
Bergan S; Bremer S; Vethe NT
Clin Biochem; 2016 Mar; 49(4-5):411-8. PubMed ID: 26453533
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic principles of immunosuppressive drugs.
Budde K; Glander P
Ann Transplant; 2008; 13(3):5-10. PubMed ID: 18806727
[TBL] [Abstract][Full Text] [Related]
3. Assay validation of phosphorylated S6 ribosomal protein for a pharmacodynamic monitoring of mTOR-inhibitors in peripheral human blood.
Dieterlen MT; Bittner HB; Klein S; von Salisch S; Mittag A; Tárnok A; Dhein S; Mohr FW; Barten MJ
Cytometry B Clin Cytom; 2012 May; 82(3):151-7. PubMed ID: 22213594
[TBL] [Abstract][Full Text] [Related]
4. Target Enzyme Activity and Phosphorylation of Pathway Molecules As Specific Biomarkers in Transplantation.
Budde K; Sommerer C; Rissling O; Dieterlen MT; Barten MJ
Ther Drug Monit; 2016 Apr; 38 Suppl 1():S43-9. PubMed ID: 26977999
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamic monitoring of the immunosuppressive therapy in patients after heart transplantation: whole blood flow cytometric analysis of lymphocyte function.
Barten MJ; Rahmel A; Boldt A; Dhein S; Bittner HB; Tarnok A; Mohr FW; Gummert JF
Comput Biol Med; 2007 Oct; 37(10):1367-73. PubMed ID: 17182025
[TBL] [Abstract][Full Text] [Related]
6. Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference.
Wallemacq P; Armstrong VW; Brunet M; Haufroid V; Holt DW; Johnston A; Kuypers D; Le Meur Y; Marquet P; Oellerich M; Thervet E; Toenshoff B; Undre N; Weber LT; Westley IS; Mourad M
Ther Drug Monit; 2009 Apr; 31(2):139-52. PubMed ID: 19177031
[TBL] [Abstract][Full Text] [Related]
7. Monitoring of inosine monophosphate dehydrogenase activity as a biomarker for mycophenolic acid effect: potential clinical implications.
Weimert NA; Derotte M; Alloway RR; Woodle ES; Vinks AA
Ther Drug Monit; 2007 Apr; 29(2):141-9. PubMed ID: 17417067
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamic monitoring of nuclear factor of activated T cell-regulated gene expression in liver allograft recipients on immunosuppressive therapy with calcineurin inhibitors in the course of time and correlation with acute rejection episodes--a prospective study.
Steinebrunner N; Sandig C; Sommerer C; Hinz U; Giese T; Stremmel W; Zahn A
Ann Transplant; 2014 Jan; 19():32-40. PubMed ID: 24457606
[TBL] [Abstract][Full Text] [Related]
9. Reduced residual gene expression of nuclear factor of activated T cells-regulated genes correlates with the risk of cytomegalovirus infection after liver transplantation.
Steinebrunner N; Sandig C; Sommerer C; Hinz U; Giese T; Stremmel W; Zahn A
Transpl Infect Dis; 2014 Jun; 16(3):379-86. PubMed ID: 24666466
[TBL] [Abstract][Full Text] [Related]
10. How pharmacokinetic and pharmacodynamic drug monitoring can improve outcome in solid organ transplant recipients.
Klupp J; Holt DW; van Gelder T
Transpl Immunol; 2002 May; 9(2-4):211-4. PubMed ID: 12180833
[TBL] [Abstract][Full Text] [Related]
11. Target enzyme activity as a biomarker for immunosuppression.
Glander P; Budde K
Ther Drug Monit; 2010 Jun; 32(3):257-60. PubMed ID: 20431505
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and pharmacodynamics of immunosuppressive drugs in elderly kidney transplant recipients.
Shi YY; Hesselink DA; van Gelder T
Transplant Rev (Orlando); 2015 Oct; 29(4):224-30. PubMed ID: 26048322
[TBL] [Abstract][Full Text] [Related]
13. Pharmacology and toxicology of mycophenolate in organ transplant recipients: an update.
Staatz CE; Tett SE
Arch Toxicol; 2014 Jul; 88(7):1351-89. PubMed ID: 24792322
[TBL] [Abstract][Full Text] [Related]
14. A novel approach in clinical immunosuppression monitoring: drug lymphocyte level.
Barbari A; Masri M; Stephan A; Rizk S; Younan F
Exp Clin Transplant; 2007 Dec; 5(2):643-8. PubMed ID: 18194115
[TBL] [Abstract][Full Text] [Related]
15. Inosine monophosphate dehydrogenase activity in renal allograft recipients during mycophenolate treatment.
Vethe NT; Mandla R; Line PD; Midtvedt K; Hartmann A; Bergan S
Scand J Clin Lab Invest; 2006; 66(1):31-44. PubMed ID: 16464785
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamic monitoring by residual NFAT-regulated gene expression in stable pediatric liver transplant recipients.
Billing H; Breil T; Schmidt J; Tönshoff B; Schmitt CP; Giese T; Engelmann G
Pediatr Transplant; 2012 Mar; 16(2):187-94. PubMed ID: 22360403
[TBL] [Abstract][Full Text] [Related]
17. Biomarkers as a tool for management of immunosuppression in transplant patients.
Wieland E; Olbricht CJ; Süsal C; Gurragchaa P; Böhler T; Israeli M; Sommerer C; Budde K; Hartmann B; Shipkova M; Oellerich M
Ther Drug Monit; 2010 Oct; 32(5):560-72. PubMed ID: 20814352
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological surrogates of allograft outcome.
Mahalati K; Kahan BD
Ann Transplant; 2000; 5(2):14-23. PubMed ID: 11217202
[TBL] [Abstract][Full Text] [Related]
19. Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure.
Tett SE; Saint-Marcoux F; Staatz CE; Brunet M; Vinks AA; Miura M; Marquet P; Kuypers DR; van Gelder T; Cattaneo D
Transplant Rev (Orlando); 2011 Apr; 25(2):47-57. PubMed ID: 21190834
[TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamic monitoring of cyclosporin A reveals risk of opportunistic infections and malignancies in renal transplant recipients 65 years and older.
Sommerer C; Schnitzler P; Meuer S; Zeier M; Giese T
Ther Drug Monit; 2011 Dec; 33(6):694-8. PubMed ID: 22105585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
